Application of CRISPR‐Cas9 technology in diabetes research

Abstract Diabetes is a chronic disorder with rapidly increasing prevalence that is a major global issue of our current era. There are two major types of diabetes. Polygenic forms of diabetes include type 1 diabetes (T1D) and type 2 diabetes (T2D) and its monogenic forms are maturity‐onset diabetes of the young (MODY) and neonatal diabetes mellitus (NDM). There are no permanent therapeutic approaches for diabetes and current therapies rely on regular administration of various drugs or insulin injection. Recently, gene editing strategies have offered new promise for treating genetic disorders. Targeted genome editing is a fast‐growing technology, recruiting programmable nucleases to specifically modify target genomic sequences. These targeted nucleases generate double‐strand breaks at target regions in the genome, which induce cellular repair pathways including non‐homologous end joining (NHEJ) and homology‐directed repair (HDR). Clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) is a novel gene‐editing system, permitting precise genome modification. CRISPR/Cas9 has great potential for various applications in diabetic research such as gene screening, generation of diabetic animal models and treatment. In this article, gene‐editing strategies are summarized with a focus on the CRISPR/Cas9 approach in diabetes research.